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ABSTRACT
Several studies have demonstrated that patho-
genic and therapeutic differences exist among
hepatitis B virus (HBV) genotypes. Therefore, this
study established the prevalence of different HBV
genotypes in 128 Belgian patients with chronic
HBV infection. The prevalences of genotypes A
and D, and mixed genotypes A and D, were 53%,
37% and 8%, respectively, for a group of blood
donors, and 54%, 31% and 9%, respectively, for a
group of patients from the gastroenterology units.
The results indicated that genotypes A and D are
the predominant genotypes in Belgian patients
with chronic HBV infection.
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Worldwide, c. 2 billion individuals show evidence
of past or current infection with hepatitis B virus
(HBV), and 350 million individuals are estimated
to have chronic infection. The virus can cause
acute hepatitis and various forms of chronic
infection, ranging from an asymptomatic chronic
carrier state to chronic hepatitis, liver cirrhosis
and hepatocellular carcinoma [1,2]. HBV is a
DNA virus with a partially circular double-stran-
ded genome of c. 3200 bp, consisting of four
overlapping open reading frames: the surface (S)
gene, encoding the virus envelope; the core (C)
gene, encoding the nucleocapsid; the X gene,
encoding the X protein; and the polymerase (P)
gene, encoding a polymerase with reverse tran-
scriptase activity [3,4].
Based on an intergroup divergence of ‡ 8% of
the entire nucleotide sequence, HBV has been
classiﬁed into eight (A–H) genotypes [5–8] with
geographically distinct distributions [3,6–8].
Although some studies have not found an associ-
ation between genotype and clinical outcome or
response to therapy [9,10], others have demon-
strated pathogenic and therapeutic differences
among the genotypes [1,11–14]. Therefore, the
aim of the present study was to establish the
prevalence of the different HBV genotypes in
Belgium.
Two groups of patients were included in the
study. Group I (n = 1564) comprised individuals
who had been rejected as blood donors following
initial screening. These sera were collected
between 1991 and 2002 at Flemish transfusion
centres. Demographic data and clinical informa-
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tion from these potential blood donors were not
available. Group II (n = 323) comprised patients
whose sera were collected during 2003 at the
gastroenterology units of three university hospi-
tals in Antwerp, Brussels and Ghent. These sera,
with demographic data on each patient collected
via a questionnaire, were sent to the National
Centre of Viral Hepatitis, where the sera were
stored at a maximum temperature of ) 20C.
Samples with evidence of chronic HBV infection,
i.e., positive for hepatitis B surface antigen
(HBsAg) and anti-hepatitis B core (HBc), but
negative for anti-HBc IgM, and with a detectable
level of HBV DNA, were selected for HBV
genotyping. As a result, 128 samples (93 samples
from group I and 35 samples from group II) were
genotyped. All 93 samples in group I came from
Flanders; of the 35 samples in group II, 22 were
from Flanders, seven from Brussels, and two from
southern Belgium (the precise region was not
known for four patients, because the question-
naire was not completed fully). Demographic
data for the individuals in group I were not
available; data for the 35 patients in group II are
shown in Table 1.
The presence of HBsAg, total anti-HBc and
anti-HBc IgM was detected by either radioimmu-
noassay (DiaSorin, Saluggia, Italy) or ELISA
(DiaSorin). The presence of hepatitis B e-antigen
(HBeAg) and antibody to HBeAg (anti-HBe) was
assessed by enzyme immunoassay (Abbott,
Wiesbaden, Germany). HBV genotypes were
determined by line probe assay (Inno-Lipa HBV
Genotyping; Innogenetics, Gent, Belgium) follow-
ing the manufacturer’s recommended procedure.
Data were analysed using the chi-square analysis
of contingency table, Fisher’s exact test, or one-
way analysis of variance, as appropriate. A p
value of < 0.05 was considered signiﬁcant.
The characteristics of the 128 patients with
chronic HBV infection, grouped according to
HBV genotype, are shown in Table 1. In group
II, genotypes A and D predominated in all age
groups. No signiﬁcant difference in mean age was
found between the four groups (A, D, A ⁄D,
others). Patients with genotype D infection
seemed to have a lower male-to-female ratio
(2.7:1) than patients with genotype A infection
(18:1), although this was probably caused by the
unequal gender ratio in the patient group studied
(29:6).
When the HBeAg ⁄ anti-HBe status for groups I
and II was analysed, no signiﬁcant differences
were found in the positivity rate of HBeAg and
anti-HBe for genotypes A and D.
In group I, the HBV genotype distribution
was: A, 49 (53%); D, 34 (37%); A ⁄D, 7 (8%); B,
1 (1%); F, 1 (1%); and unclassiﬁed, 1 (1%). In
group II, the distribution was: A, 19 (54%);
D, 11 (31%); A ⁄D, 3 (9%); E, 1 (3%); and
unclassiﬁed, 1 (3%). No signiﬁcant difference
was observed with respect to the distribution of
genotypes A, D and A ⁄D between the two
groups. Thus, although the blood donors (group
I) belonged to a selected population, there was
no signiﬁcant difference between the two
groups with respect to the distribution of
genotypes A, D and A ⁄D. It therefore seems
that genotypes A and D are the predominant
genotypes in Belgium, a ﬁnding that corrobor-
ates the results of other European studies
[11,15,16]. The prevalence rates of genotype A
(53% and 54%) and D (37% and 31%) were
similar to the prevalences reported in a study of
Spanish patients with chronic HBV infection
(genotype A, 52%; genotype D, 35%) [11]. In a
manner similar to infection with hepatitis C or
hepatitis D virus [17,18], mixed infection with
different genotypes of HBV may occur [12].
However, as has been reported from India
[12], mixed infections with genotypes A and D
Table 1. Characteristics of individuals with chronic hepa-
titis B virus (HBV) infection, grouped according to HBV
genotype
All
cases
Genotype
A
Genotype
D
Genotypes
A ⁄D
Other
genotypes
(B, F, E, U)
Number of cases 128 68 (53) 45 (35) 10 (8) 5 (4)
Blood donors
(group I)
93 49 (53) 34 (37)a 7 (8) 3 (3)
HBeAg +ve 8 5 (63) 2 (25) 1 (13) 0 (0)
Anti-HBe +ve 77 39 (51) 29 (38) 7 (9) 2 (3)
Patients from
gastroenterology
units
(group II)
35 19 (54) 11 (31)a 3 (9) 2 (6)
HBeAg +ve 12 4 (33) 5 (42) 1 (8) 2 (17)
Anti-HBe +ve 23 15 (65) 5 (22) 3 (13) 0 (0)
Male ⁄ female ratio 29:6 18:1 8:3 1:2 2:0
Mean age
(years) ± SD
41 ± 13 42 ± 13 41 ± 14 38 ± 11 34 ± 3
Age groups
20–29 8 4 3 1 0
30–39 12 6 3 1 2
40–49 6 3 2 1 0
50–59 4 3 1 0 0
‡ 60 5 3 2 0 0
Figures in parentheses denote percentages.
A ⁄D, mixed genotypes A and D; U, unclassiﬁed genotype by the line probe assay,
despite detection of HBV DNA.
aThe HBeAg ⁄ anti-HBe status of one sample from this group could not be
determined because of insufﬁcient serum.
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were seen only in a small proportion of the
samples (8% and 9% for groups I and II,
respectively).
Genotypes B and F were each detected in only
one sample from a blood donor in group I.
Generally, these genotypes are encountered only
in certain parts of the world, i.e., Asia and South
America, respectively. These two blood donors
may have originated from these areas, but this
information was not available. Genotype E was
detected in only one patient from a gastroenter-
ology unit (a Belgian of foreign origin, which
could explain this unusual result).
In conclusion, the ﬁndings of this study indi-
cate that genotypes A and D are predominant in
Belgian patients with chronic HBV infection.
However, as the sample size in this study was
rather small and most individuals studied were
from Flanders, further larger studies are needed
to conﬁrm this ﬁnding.
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